Market report: Biotech stocks rise for yet another week
10 December, 2010 by David BinningThe S&P/ASX 200 Heathcare Index continued its march towards 9000 points this week as the broader market eked out a small gain for the second week in a row.
Market report: Biotechs up for fourth week in a row
03 December, 2010 by David BinningThe S&P/ASX 200 Heathcare Index close in the black for the fourth week in a row today, partly buoyed by a strong come back from the wider market, which snapped its losing streak.
vivoPharm opening for business in the U.S
26 November, 2010 by Staff WritersAdelaide-based contract research organisation vivoPharm has received $US1.3 million to help fund building of the company’s first facility in the U.S.
Australian researchers claim cure for high blood pressure
19 November, 2010 by David BinningResearchers at the Baker IDI Heart and Diabetes Institute in Melbourne have released the results of an international patient trial of a novel new treatment based on radio waves which they say has the potential to revolutionise treatment for blood pressure and other conditions.
Feature: Designing drought tolerant crops
15 November, 2010 by Graeme O'NeillIn the past decade, the zero-till revolution has rolled across wheat farms on the margins of the arid zone in south-eastern Australia, helping wheat growers survive the longest and deepest drought since European settlement.
Anti-GM activists hijack Economist debate on biotechnology and agriculture
13 November, 2010 by Tim DeanBritish news and analysis magazine, The Economist, has announced the results of its recent debate on biotechnology and sustainable agriculture finding a majority of voters in opposition of the motion, yet suggesting that technical difficulties and a coordinated effort by anti-GM activists has skewed the result.
HealthLinx reports strong results from ovarian cancer study
12 November, 2010 by Staff WritersShares in diagnostics company HealthLinx surged 18 percent today after the company announced positive results from its independent, multi-centre, multi-site second study for OvPlex based on two new biomarkers being evaluated as diagnostics for ovarian cancer.
Patrys reports positive early stage data from melanoma clinical trial
10 November, 2010 by Staff WritersShares in Melbourne biotech Patrys jumped by 15 per cent by late morning today after the company announced that it has completed treatment of the first patient group in the melanoma trial of its natural human antibody product PAT-SM6.
LCT moves closer to Parkinson’s cure
10 November, 2010 by David BinningLiving Cell Technologies reported today that its NTCELL cell implant product for neurodegenerative conditions has demonstrated effectiveness in two pre-clinical models of Parkinson's disease.
Beta blockers shown to combat osteoporosis
09 November, 2010 by Staff WritersResearchers from Sydney’s Garvan Institute of Medical Research have shown that beta blockers can increase bone density and reduce the risk of osteoporotic fracture in around 50 per cent of patients.
Feature: Algal biofuels and the future of renewable energy
05 November, 2010 by Fiona WylieA group of specially adapted green algae may hold the answer to sustainable and renewable energy for the future, helped by the Sun and more than a pinch of clever science.
Feature: The meaning of (artificial) life
04 November, 2010 by Tim DeanIt was once widely believed that life differed fundamentally from non-life; the defining characteristic of life was the existence of some insubstantial vital force – an élan vital – for which no physical process could account.
Life Research expands portfolio with acquisition of Mimotopes
04 November, 2010 by Staff WritersLife Research has added the peptide portfolio of Mimotopes to its repertoire with the acquisition of the company from its parent, Commonwealth Biotechnologies, by Leadtec Systems.
Novotech kicks off Phase Ib trials in Australia and NZ for OncoMed
03 November, 2010 by Staff WritersCalifornia-based biopharma company, OncoMed Pharmaceuticals, has announced it will run three Phase Ib clinical trials in Australia and New Zealand testing its humanised monoclonal antibody therapies for cancer via local CRO, Novotech.
Holista signs ‘halal’ deals in Malaysia
03 November, 2010 by Staff WritersListed Australian biotech Holista CollTech announced today that it has signed two significant deals regarding the research and commercialisation of its halal food-grade sheep collagen.
